116 related articles for article (PubMed ID: 7914235)
1. A randomized, placebo-controlled, blind anti-AIDS clinical trial: safety and immunogenicity of a specific anti-IFN alpha immunization.
Gringeri A; Santagostino E; Mannucci PM; Tradati F; Cultraro D; Buzzi A; Criscuolo M; David A; Guillemot L; Barré-Sinoussi F
J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):978-88. PubMed ID: 7914235
[TBL] [Abstract][Full Text] [Related]
2. Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study).
Gringeri A; Musicco M; Hermans P; Bentwich Z; Cusini M; Bergamasco A; Santagostino E; Burny A; Bizzini B; Zagury D
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Apr; 20(4):358-70. PubMed ID: 10096580
[TBL] [Abstract][Full Text] [Related]
3. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.
Kelleher AD; Roggensack M; Jaramillo AB; Smith DE; Walker A; Gow I; McMurchie M; Harris J; Patou G; Cooper DA
AIDS; 1998 Jan; 12(2):175-82. PubMed ID: 9468366
[TBL] [Abstract][Full Text] [Related]
5. Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up report.
Gringeri A; Santagostino E; Cusini M; Muça-Perja M; Marinoni A; Mannucci PM; Burny A; Criscuolo M; Lu W; Andrieru JM; Mbika JP; Lachgar A; Fall LS; Chams V; Feldman M; Hermans P; Zagury JF; Bizzini B; Musicco M; Zagury D
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Sep; 13(1):55-67. PubMed ID: 8797687
[TBL] [Abstract][Full Text] [Related]
6. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up.
Levine AM; Groshen S; Allen J; Munson KM; Carlo DJ; Daigle AE; Ferre F; Jensen FC; Richieri SP; Trauger RJ; Parker JW; Salk PL; Salk J
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(4):351-64. PubMed ID: 8601221
[TBL] [Abstract][Full Text] [Related]
7. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.
DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W
J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy.
Asjö B; Stavang H; Sørensen B; Baksaas I; Nyhus J; Langeland N
AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1357-65. PubMed ID: 12487807
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of HIV-seropositive patients: preliminary report on a dose-ranging study.
Slade H; Turner J; Abrams C; Carlo D; Salk J
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1329-31. PubMed ID: 1361349
[No Abstract] [Full Text] [Related]
10. A therapeutic HIV-1 vaccine enhances anti-HIV-1 immune responses in patients under highly active antiretroviral therapy.
Tung FY; Tung JK; Pallikkuth S; Pahwa S; Fischl MA
Vaccine; 2016 Apr; 34(19):2225-32. PubMed ID: 27002500
[TBL] [Abstract][Full Text] [Related]
11. Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon α-2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial.
Leal L; Couto E; Sánchez-Palomino S; Climent N; Fernández I; Miralles L; Romero Y; González T; Maleno MJ; Paño B; Pich J; Nicolau C; Gatell JM; Plana M; García F;
Front Immunol; 2021; 12():767370. PubMed ID: 34858423
[TBL] [Abstract][Full Text] [Related]
12. Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946).
Kundu-Raychaudhuri S; Sevin A; Kilgo P; Nokta M; Pollard RB; Merigan TC
AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1371-8. PubMed ID: 11679149
[TBL] [Abstract][Full Text] [Related]
13. Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial.
Boffito M; Fox J; Bowman C; Fisher M; Orkin C; Wilkins E; Jackson A; Pleguezuelos O; Robinson S; Stoloff GA; Caparrós-Wanderley W
Vaccine; 2013 Nov; 31(48):5680-6. PubMed ID: 24120550
[TBL] [Abstract][Full Text] [Related]
14. Delayed-type hypersensitivity responses to HIV Gag p24 relate to clinical outcome after peptide-based therapeutic immunization for chronic HIV infection.
Kran AM; Sommerfelt MA; Baksaas I; Sørensen B; Kvale D
APMIS; 2012 Mar; 120(3):204-9. PubMed ID: 22339677
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant T cell epitopes: safety, immunogenicity, and feasibility in Guinea-Bissau.
Román VR; Jensen KJ; Jensen SS; Leo-Hansen C; Jespersen S; da Silva Té D; Rodrigues CM; Janitzek CM; Vinner L; Katzenstein TL; Andersen P; Kromann I; Andreasen LV; Karlsson I; Fomsgaard A
AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1504-12. PubMed ID: 23634822
[TBL] [Abstract][Full Text] [Related]
16. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.
Mpendo J; Mutua G; Nyombayire J; Ingabire R; Nanvubya A; Anzala O; Karita E; Hayes P; Kopycinski J; Dally L; Hannaman D; Egan MA; Eldridge JH; Syvertsen K; Lehrman J; Rasmussen B; Gilmour J; Cox JH; Fast PE; Schmidt C
PLoS One; 2015; 10(8):e0134287. PubMed ID: 26252526
[TBL] [Abstract][Full Text] [Related]
17. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.
Zagury JF; Sill A; Blattner W; Lachgar A; Le Buanec H; Richardson M; Rappaport J; Hendel H; Bizzini B; Gringeri A; Carcagno M; Criscuolo M; Burny A; Gallo RC; Zagury D
J Hum Virol; 1998; 1(4):282-92. PubMed ID: 10195253
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial.
Salmon-Céron D; Durier C; Desaint C; Cuzin L; Surenaud M; Hamouda NB; Lelièvre JD; Bonnet B; Pialoux G; Poizot-Martin I; Aboulker JP; Lévy Y; Launay O;
AIDS; 2010 Sep; 24(14):2211-23. PubMed ID: 20625264
[TBL] [Abstract][Full Text] [Related]
19. Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study.
Iaria ML; Fiorentini S; Focà E; Zicari S; Giagulli C; Caccuri F; Francisci D; Di Perri G; Castelli F; Baldelli F; Caruso A
Vaccine; 2014 Feb; 32(9):1072-8. PubMed ID: 24456624
[TBL] [Abstract][Full Text] [Related]
20. Anti-IFN alpha immunization raises the IFN alpha-neutralizing capacity of serum--an adjuvant to antiretroviral tritherapy.
Zagury D; Lecoq H; Gervi I; Le Buanec H; Zagury JF; Bizzini B; Burny A; Hermans P; Perja M; Santagostino E; Gringeri A
Biomed Pharmacother; 1999 Mar; 53(2):90-2. PubMed ID: 10337463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
